前列腺癌肉瘤占所有前列腺肿瘤的<1%。关于这种疾病的文献仅限于少数案例研究，主要是由于这种恶性肿瘤的罕见性。我们的目的是调查前列腺癌肉瘤的人口统计学、临床和组织学因素、预后和生存率。使用监测、流行病学和最终结果 (SEER) 数据库来识别 2000 年至 2018 年的前列腺癌肉瘤患者。记录人口统计和临床数据，包括年龄、种族、性别、肿瘤分级、分期、肿瘤大小、淋巴结状态、转移和治疗方式。前列腺癌肉瘤诊断时的中位年龄为 72 岁，大多数病例白人（93%）。报告时，组织学分级包括中分化（3.3%）、低分化（56.7%）和未分化/间变（40%）亚型。在有报告数据的患者中，肿瘤大小在 2-5 cm (15.8%) 和 >5 cm (84.2%) 之间变化。远处转移最常见于肝脏（12.5%）和肺（12.5%），其次是骨（8.3%）。最常见的治疗方法是放疗手术（32.4%）。五年总生存率为 11.9%。前列腺癌肉瘤影响七十岁的男性。区域和远处肿瘤分期被认为是生存的指标。前列腺癌肉瘤很少见；由于其侵袭性，更深入的了解和改进的个性化治疗方法对于在这个充满挑战的肿瘤学领域改善患者的治疗结果是必要的。

Prostatic carcinosarcoma comprises <1% of all prostate neoplasms. The literature on this disease is limited to a few case studies, primarily due to the rarity of this malignancy. We aimed to investigate the demographic, clinical, and histologic factors, prognosis, and survival of prostatic carcinosarcoma.The Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients with prostatic carcinosarcoma from 2000-2018. Demographic and clinical data, including age, race, sex, tumor grade, stage, tumor size, lymph node status, metastasis, and treatment modalities, were recorded.Prostatic carcinosarcoma had a median age of 72 years at diagnosis, with a majority of cases among White individuals (93%). When reported, the histologic grade comprised moderately differentiated (3.3%), poorly differentiated (56.7%), and undifferentiated/anaplastic (40%) subtypes. In patients with reported data, tumor size varied between 2-5 cm (15.8%) and >5 cm (84.2%). Distant metastasis most commonly occurred in the liver (12.5%) and lung (12.5%), followed by the bone (8.3%). The most common treatment performed was surgery with radiation (32.4%). The five-year overall survival was 11.9%.Prostatic carcinosarcoma affects men in the seventh decade of life. Regional and distant tumor stage is considered an indicator of survival. Prostate carcinosarcoma is rare; due to its aggressive nature, a deeper understanding, and an improved personalized therapeutic approach are necessary for improving patient outcomes in this challenging arena of oncology.